Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Builds Sales On Smoking Cessation, Eyes Prilosec OTC In 2007

This article was originally published in The Tan Sheet

Executive Summary

Pursuit of private-label omeprazole for a possible 2007 launch fits Perrigo's ongoing strategy of focusing on new products to drive sales growth
Advertisement

Related Content

Employers Could Be Hot Target For OTC Smoking-Cessation Sales – Survey
Employers Could Be Hot Target For OTC Smoking-Cessation Sales – Survey
Employers Could Be Hot Target For OTC Smoking-Cessation Sales – Survey
Perrigo Counters Meth Act Fallout With New Products, Reformulations
Perrigo Counters Meth Act Fallout With New Products, Reformulations
Perrigo Counters Meth Act Fallout With New Products, Reformulations
Perrigo’s New Papa: CEO Brings Product Development Know-How To Post
Generic Prilosec OTC ANDA Filed By Perrigo Partner Dexcel; AstraZeneca Sues
Generic Prilosec OTC ANDA Filed By Perrigo Partner Dexcel; AstraZeneca Sues
Pseudoephedrine Will Be Behind The Counter Across The Country By October

Topics

Advertisement
UsernamePublicRestriction

Register

PS099660

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel